Insys Therapeutics (INSY) Misses Q1 EPS by 1c

Insys Therapeutics (NASDAQ: INSY) reported Q1 EPS of ($0.19), $0.01 worse than the analyst estimate of ($0.18). Revenue for the quarter came in at $23.9 million versus the consensus estimate of $25.66 million.

For earnings history and earnings-related data on Insys Therapeutics (INSY) click here.

You May Also Be Interested In

• ConAgra Brands (CAG) Tops Q1 EPS by 13c, Beats on Revenue; Offers FY27 EPS Guidance
• FactSet (FDS) Tops Q4 EPS by 17c, Beats on Revenue; Offers FY Guidance
• Yiren Digital Ltd. (YRD) Reports Q2 Loss of RMB5.11